Resource Summary Report

Generated by FDI Lab - SciCrunch.org on Apr 1, 2025

Rabbit anti-BRD4 Antibody, Affinity Purified

RRID:AB_2620184
Type: Antibody

Proper Citation

(Bethyl Cat# A301-985A100, RRID:AB_2620184)

Antibody Information

URL: http://antibodyregistry.org/AB_2620184

Proper Citation: (Bethyl Cat# A301-985A100, RRID:AB_2620184)

Target Antigen: BRD4

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: WB, IP, IHC
Original Manufacturer

Antibody Name: Rabbit anti-BRD4 Antibody, Affinity Purified

Description: This polyclonal targets BRD4

Target Organism: mouse, human

Antibody ID: AB_2620184

Vendor: Bethyl

Catalog Number: A301-985A100

Alternative Catalog Numbers: OWL-A17468

Record Creation Time: 20231110T034855+0000

Record Last Update: 20240724T235311+0000

Ratings and Alerts

No rating or validation information has been found for Rabbit anti-BRD4 Antibody, Affinity Purified.

Warning: Discontinued at Thermo Fisher Scientific
Applications: WB, IP, IHC
Original Manufacturer

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 22 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

Etoh K, et al. (2024) Citrate metabolism controls the senescent microenvironment via the remodeling of pro-inflammatory enhancers. Cell reports, 43(8), 114496.

Quintela M, et al. (2023) Bromodomain inhibitor i-BET858 triggers a unique transcriptional response coupled to enhanced DNA damage, cell cycle arrest and apoptosis in high-grade ovarian carcinoma cells. Clinical epigenetics, 15(1), 63.

Chen N, et al. (2022) YAP1 maintains active chromatin state in head and neck squamous cell carcinomas that promotes tumorigenesis through cooperation with BRD4. Cell reports, 39(11), 110970.

Czimmerer Z, et al. (2022) The epigenetic state of IL-4-polarized macrophages enables inflammatory cistromic expansion and extended synergistic response to TLR ligands. Immunity, 55(11), 2006.

Zhu X, et al. (2022) Acute depletion of human core nucleoporin reveals direct roles in transcription control but dispensability for 3D genome organization. Cell reports, 41(5), 111576.

Slaughter MJ, et al. (2021) HDAC inhibition results in widespread alteration of the histone acetylation landscape and BRD4 targeting to gene bodies. Cell reports, 34(3), 108638.

Cao Z, et al. (2021) ZMYND8-regulated IRF8 transcription axis is an acute myeloid leukemia dependency. Molecular cell, 81(17), 3604.

Kanne J, et al. (2021) Pericentromeric Satellite III transcripts induce etoposide resistance. Cell death & disease, 12(6), 530.

Lee JH, et al. (2021) Enhancer RNA m6A methylation facilitates transcriptional condensate formation and gene activation. Molecular cell, 81(16), 3368.

Choi J, et al. (2021) Evidence for additive and synergistic action of mammalian enhancers during cell fate determination. eLife, 10.

Gao M, et al. (2021) Metabolically controlled histone H4K5 acylation/acetylation ratio drives BRD4 genomic distribution. Cell reports, 36(4), 109460.

Narita T, et al. (2021) Enhancers are activated by p300/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release. Molecular cell, 81(10), 2166.

Hogg SJ, et al. (2021) Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Molecular cell, 81(10), 2183.

Marques JG, et al. (2020) NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. eLife, 9.

Xiang Y, et al. (2020) Dysregulation of BRD4 Function Underlies the Functional Abnormalities of MeCP2 Mutant Neurons. Molecular cell, 79(1), 84.

Huang Y, et al. (2019) The Leukemogenic TCF3-HLF Complex Rewires Enhancers Driving Cellular Identity and Self-Renewal Conferring EP300 Vulnerability. Cancer cell, 36(6), 630.

Mayor-Ruiz C, et al. (2019) Plasticity of the Cullin-RING Ligase Repertoire Shapes Sensitivity to Ligand-Induced Protein Degradation. Molecular cell, 75(4), 849.

Fiskus W, et al. (2019) Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells. Blood cancer journal, 9(2), 4.

Stewart E, et al. (2018) Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. Cancer cell, 34(3), 411.

Cai L, et al. (2018) ZFX Mediates Non-canonical Oncogenic Functions of the Androgen Receptor Splice Variant 7 in Castrate-Resistant Prostate Cancer. Molecular cell, 72(2), 341.